Bartonella henselae DNA in Seronegative Patients with Cat-Scratch Disease

Masashi Yanagihara, Hidehiro Tsuneoka, Ayano Tanimoto, Ken-ichiro Otsuyama, Jun Nishikawa, Tomohiro Matsui, Junzo Nojima, Kiyoshi Ichihara

Author affiliation: Yamaguchi University, Ube, Japan

DOI: https://doi.org/10.3201/eid2405.152033

We used real-time PCR to detect Bartonella henselae DNA in 7.9% (5/63) of blood specimens from seronegative patients in Japan suspected of having cat-scratch disease. The combined use of serologic tests and real-time PCR to analyze blood specimens is recommended for the prompt, noninvasive laboratory diagnosis of cat-scratch disease.

Cat-scratch disease (CSD) is a worldwide zoonosis caused by Bartonella henselae (1). Its clinical manifestations vary from typical CSD with regional lymphadenopathy to atypical or systemic CSD, including prolonged fever without lymphadenopathy. Because isolation of B. henselae by culture is difficult (2), detection of B. henselae DNA in lymph nodes by PCR and serologic testing using indirect fluorescence antibody (IFA) assay is widely used for laboratory diagnosis of CSD (2–4). Isolation of B. henselae DNA from blood specimens of immunocompetent CSD patients has been sporadically described, suggesting that it might be useful, especially for cases in which lymphadenectomy or biopsy is not feasible or serologic results are equivocal (5–9). However, the usefulness of serologic testing, coupled with detection of B. henselae DNA from blood specimens, is not well described. We report the clinical utility of the combined use of IFA and real-time PCR to analyze blood specimens for noninvasive screening of CSD.

During April 2009–May 2014, eighty immunocompetent patients (73 children, 7 adults) in Japan who were suspected of having CSD because of fever with or without lymphadenopathy, and a history of contact with cats or dogs were referred to us for serologic and molecular diagnosis of CSD. We conducted serologic testing using IFA (3,4); diagnosis was based on elevated titer of IgM (≥20) or IgG (≥256). The sensitivity and specificity of our IFA were 69% and 100%, respectively (4). Real-time PCR (rPCR) detected specific B. henselae virB4 DNA from blood specimens as reported previously (9). In brief, we extracted DNA from peripheral blood using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). The 20-µL PCR mixture contained 10 µL 2× LightCycler 480 Probes Master Mix (Roche Diagnostics, Mannheim, Germany), 0.4 µmol/L of each primer (forward: 5′-AGCGAGAAAAACACATCTGAA-3′; reverse: 5′-TCCATAGTTTTCCAATCTTCT-3′), 0.1 µmol/L Universal ProbeLibrary probe no. 135 (Roche Diagnostics), and 5 µL DNA. We conducted the reaction using a LightCycler 480 instrument (Roche Diagnostics) under the following conditions: denaturation at 95°C for 5 min and 45 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 1 s. We determined crossing point (Cp) values using the second-derivative maximum method and analyzed all samples in triplicate.

This assay detected all 56 specimens evaluated as B. henselae (10), but other Bartonella species were not identified (9). The lower quantitative detection limit of this assay was 4.6 DNA copies/reaction using serial dilutions of plasmid DNA.

Of the 80 patients with suspected CSD, 17 (21.3%) were serologically positive for B. henselae by IFA. B. henselae DNA was amplified from the peripheral blood of 11 (13.8%) patients by rPCR. Six patients were positive by both IFA and rPCR. CSD was diagnosed in 22 (27.5%) of the 80 patients (Table). Cp values of the IFA-positive and -negative patients did not differ.

Despite the high specificity, IFA lacks sensitivity (4). This study showed that CSD detection sensitivity increased from 21.3% (17/80) using IFA alone to 27.5% (22/80) with combined use of IFA and rPCR on blood specimens. We attribute this increase to the detection of B. henselae DNA in 5 patients with seronegative results. Four patients (nos. 6, 8, 10, and 17) exhibited typical CSD with fever and regional lymphadenopathy, and 1 (no. 3) had fever of unknown origin without lymphadenopathy (Table). After laboratory diagnosis, these patients were treated with macrolides to reduce fever. These observations suggested that these patients were in the initial stages of the illness (before a significant rise of antibodies to B. henselae) or that the patients’ immune responses were insufficient to produce antibodies to B. henselae (5).

We detected B. henselae DNA in blood specimens of 35.3% (6/17) of the seropositive patients in our study, whereas previous studies detected DNA in 19.2% (5/26) of blood specimens from seropositive patients (5) and 16.7% (3/18) of serum specimens from patients proven to have CSD (6). rPCR using blood specimens was not sensitive enough when used alone because B. henselae DNA is not present in the bloodstream in all patients. The time points at which B. henselae DNA can be detected in blood specimens are still unknown. A previous report described this time point as 3 weeks after onset of lymphadenopathy (7), whereas another study considered it to be 3–4 months after infection (8). Most specimens used in our study were
collected within 3 weeks after symptom onset. Regardless of the days after onset, rPCR testing of blood specimens should be performed actively because patients may experience bacteremia or the shedding of bacterial breakdown products into the bloodstream.

In conclusion, our study showed that rPCR testing of blood specimens can detect \textit{B. henselae} DNA in patients with seronegative results. The combined use of IFA and rPCR on blood specimens is useful for the noninvasive screening of CSD.

This work was supported by Japan Society for the Promotion of Science KAKENHI (Grant-in-Aid for Young Scientists [B]) grant no. 24790554.

About the Author

Dr. Yanagihara is an assistant professor in the Department of Laboratory Sciences, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine. His primary research interest is \textit{B. henselae} infection.

References


Address for correspondence: Masashi Yanagihara, Yamaguchi University Graduate School of Medicine—Department of Laboratory Sciences, Faculty of Health Sciences, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan, email: m-yanagi@yamaguchi-u.ac.jp